Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dupixent
Biotech
Sanofi CFO defends Hudson's legacy, accepts R&D ‘setbacks’
As Sanofi counts down before its new leader arrives, the pharma's CFO acknowledged to Fierce that there have been a “certain number of setbacks.”
James Waldron
Apr 23, 2026 4:04am
Connect’s Dupixent rival hits the mark in phase 3 eczema trial
Mar 30, 2026 9:32am
Dupixent for cancer? Researchers test med as PD-1 booster
Dec 7, 2023 6:00am
Celldex laces up next to Big Pharmas with chronic hive drug
Nov 6, 2023 10:17am
2 biotechs test icy IPO waters with $228M and $66M offerings
Jul 10, 2023 11:43am
Aslan hopes to take on Dupixent in AD with fewer side effects
Jul 6, 2023 11:20am
